SMARCE1 and ovarian cancer: The overall survival of ovarian cancer patients with high expression levels of SMARCE1 was more likely to show relapse with metastases over a follow-up period of more than 15 y [n = 1,435, hazard ratio (HR) = 1.19, P = 0.019] (SI Appendix, Fig. S2).